scholarly journals Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 )

2018 ◽  
Vol 20 (7) ◽  
pp. 594-603 ◽  
Author(s):  
Patricia D Walshaw ◽  
Laszlo Gyulai ◽  
Michael Bauer ◽  
Mark S Bauer ◽  
Brian Calimlim ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Thyroid Hormone ◽  
Controlled Trial ◽  
Hormone Treatment ◽  
Rapid Cycling ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder

2012 ◽  
Vol 14 (7) ◽  
pp. 780-789 ◽  
Author(s):  
David E Kemp ◽  
Keming Gao ◽  
Elizabeth B Fein ◽  
Philip K Chan ◽  
Carla Conroy ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Controlled Trial ◽  
Lessons Learned ◽  
Rapid Cycling ◽  
Double Blind ◽  
Double Blind Placebo

A double-blind, placebo-controlled trial of eicosapentanoic acid in rapid cycling bipolar disorder

2002 ◽  
Vol 4 ◽  
pp. 26-27 ◽  
Author(s):  
Paul E Keck ◽  
Marlene P Freeman ◽  
Susan L McElroy ◽  
Lori L Altshuler ◽  
Kirk D Denicoff ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Controlled Trial ◽  
Rapid Cycling ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Eicosapentanoic Acid

Double-Blind, Placebo-Controlled Trial of Divalproex Monotherapy in the Treatment of Symptomatic Youth at High Risk for Developing Bipolar Disorder

2007 ◽  
Vol 68 (05) ◽  
pp. 781-788 ◽  
Author(s):  
Robert L. Findling ◽  
Thomas W. Frazier ◽  
Eric A. Youngstrom ◽  
Nora K. McNamara ◽  
Robert J. Stansbrey ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
High Risk ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence

2014 ◽  
Vol 38 (7) ◽  
pp. 2113-2118 ◽  
Author(s):  
E. Sherwood Brown ◽  
Domingo Davila ◽  
Alyson Nakamura ◽  
Thomas J. Carmody ◽  
A. John Rush ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Alcohol Dependence ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals A Randomized, Double-Blind, Placebo-Controlled, Trial of Lamotrigine Therapy in Bipolar Disorder, Depressed or Mixed Phase and Cocaine Dependence

2012 ◽  
Vol 37 (11) ◽  
pp. 2347-2354 ◽  
Author(s):  
E Sherwood Brown ◽  
Prabha Sunderajan ◽  
Lisa T Hu ◽  
Sharon M Sowell ◽  
Thomas J Carmody
Keyword(s):  
Bipolar Disorder ◽  
Controlled Trial ◽  
Cocaine Dependence ◽  
Mixed Phase ◽  
Double Blind ◽  
Double Blind Placebo

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

2000 ◽  
Vol 61 (11) ◽  
pp. 841-850 ◽  
Author(s):  
Joseph R. Calabrese ◽  
Trisha Suppes ◽  
Charles L. Bowden ◽  
Gary S. Sachs ◽  
Alan C. Swann ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Rapid Cycling ◽  
Double Blind ◽  
Double Blind Placebo

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

2009 ◽  
Vol 21 (6) ◽  
pp. 285-291 ◽  
Author(s):  
Michelle Bernardo ◽  
Seetal Dodd ◽  
Clarissa S. Gama ◽  
David L Copolov ◽  
Olivia Dean ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Bipolar Disorder ◽  
Substance Use ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Other Substances

Objective:To evaluate the effect of N-acetylcysteine (NAC) on substance use in a double-blind, placebo-controlled trial of NAC in bipolar disorder. It is hypothesised that NAC will be superior to placebo for reducing scores on the Clinical Global Impressions scale for Substance Use (CGI-SU).Methods:Participants were randomised to a 6-months of treatment with 2 g/day NAC (n = 38) or placebo (n = 37). Substance use was assessed at baseline using a Habits instrument. Change in substance use was assessed at regular study visits using the CGI-SU.Results:Among the 75 participants 78.7% drank alcohol (any frequency), 45.3% smoked tobacco and 92% consumed caffeine. Other substances were used by fewer than six participants. Caffeine use was significantly lower for NAC-treated participants compared to placebo at week 2 of treatment but not at other study visits.Conclusions:NAC appeared to have little effect on the participants who were using substances. A larger study on a substance-using population will be necessary to determine if NAC may be a useful treatment for substance use.

Sign in / Sign up

Export Citation Format

Share Document